X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Anti-GD2 CAR NKT-Cell Therapy targeting BTG1 which is identified as a novel molecular target that can be used to enhance the potency of natural killer T (NKT)- and T cell-based cancer immunotherapy. It is being developed for relapsed/refractory neuroblastoma.
Lead Product(s): GINAKIT Cell Therapy,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Baylor College of Medicine
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 15, 2023
Details:
Immunai aims to map out the whole immune system. The funds will make a hiring push and will expand its already robust research and development activities.
Lead Product(s): CAR-T cell therapies
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: UndisclosedProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Viola Group
Deal Size: $20.0 million Upfront Cash: Undisclosed
Deal Type: Financing May 15, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
